TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28219338

Group type: EXPERIMENTAL
Intervention: Home-based mixed surveillance programme (exercise at home monitored with NUUBO® device, walking at 70% HRR for 1 hour/day, 5-7 days/week for 2 months)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Traditional cardiac rehabilitation in hospital (control group)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Home-based mixed surveillance programme
Number of subjects: 28

Group type: COMPARATOR
Intervention: Traditional cardiac rehabilitation in hospital
Number of subjects: 28
Study: 26212318

Group type: EXPERIMENTAL
Intervention: Educational LARC script during postpartum hospitalization
Number of subjects: 324

Group type: COMPARATOR
Intervention: Not receiving educational LARC script
Number of subjects: 324

Group type: EXPERIMENTAL
Intervention: Reasons for non-use of LARC among interested women
Number of subjects: 324

Group type: EXPERIMENTAL
Intervention: Contraceptive methods used instead of LARC
Number of subjects: 324
Study: 23908148

Group type: EXPERIMENTAL
Intervention: Total Sleep Deprivation (TSD)
Number of subjects: 14

Group type: COMPARATOR
Intervention: One night of sleep
Number of subjects: 14
Study: 21767103

Group type: EXPERIMENTAL
Intervention: Early antiretroviral therapy (immediate therapy)
Number of subjects: 1763

Group type: COMPARATOR
Intervention: Delayed antiretroviral therapy (after decline in CD4 count or onset of symptoms)
Number of subjects: 1763
Study: 19551881

Group type: EXPERIMENTAL
Intervention: Written information plus patient navigation (TPN)
Number of subjects: 487

Group type: COMPARATOR
Intervention: Enhanced usual care (EUC)
Number of subjects: 487
Study: 17116721

Group type: EXPERIMENTAL
Intervention: Heat-killed Lactobacillus plantarum L-137 (HK-LP) 10 mg daily for 12 weeks
Number of subjects: 60
Study: 14746696

Group type: EXPERIMENTAL
Intervention: Eradicating treatment with omeprazole, amoxicillin, and clarithromycin for 7 days (group A, n = 47)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Placebo, amoxicillin, and clarithromycin for 7 days (group B, n = 46)
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Both groups (A and B)
Number of subjects: 93
Study: 11210244

Group type: EXPERIMENTAL
Intervention: Citric acid treatment
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Tetracycline hydrochloride treatment
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: EDTA treatment
Number of subjects: 36

Group type: COMPARATOR
Intervention: Root planing only
Number of subjects: 36
Study: 9505913

Group type: EXPERIMENTAL
Intervention: Intracoronary stent (group A)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Angioplasty alone (group B)
Number of subjects: 60
Study: 7529754

Group type: EXPERIMENTAL
Intervention: Topical bleomycin 1% in dimethylsulphoxide (DMSO) applied for 5 minutes for 14 consecutive days
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo (carrier)
Number of subjects: 22
Study: 3588048

Group type: EXPERIMENTAL
Intervention: Clenbuterol 0.5 micrograms/kg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Clenbuterol 1.0 micrograms/kg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Clenbuterol 1.5 micrograms/kg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 31494306

Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning (RIP)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Sham protocol (Control)
Number of subjects: 28
Study: 30567914

Group type: EXPERIMENTAL
Intervention: Pain severity
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Pain catastrophizing
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Exercise
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Depression
Number of subjects: 44
Study: 26272524

Group type: EXPERIMENTAL
Intervention: Catheter contact force (CF) during radiofrequency ablation
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: CF threshold of >8 g
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: CF threshold of >12 g
Number of subjects: 36
Study: 24093756

Group type: EXPERIMENTAL
Intervention: Medication Adherence Training Instrument (MATI)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual model medical follow-up (Control)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both MATI and Control
Number of subjects: 0
Study: 22689416

Group type: EXPERIMENTAL
Intervention: Intensive cholesterol-lowering therapy with pitavastatin (target LDL-C; 80 mg/dl)
Number of subjects: 303

Group type: COMPARATOR
Intervention: Moderate cholesterol-lowering therapy with pitavastatin (target LDL-C; 100 mg/dl)
Number of subjects: 303
Study: 21612319

Group type: EXPERIMENTAL
Intervention: Combination of azelaic acid 5% and clindamycin 2% (AA-Clin)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Clindamycin 2%
Number of subjects: 150

Group type: COMPARATOR
Intervention: Azelaic acid 5%
Number of subjects: 150
Study: 18279043

Group type: EXPERIMENTAL
Intervention: HIV infection alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: HIV infection and tuberculosis
Number of subjects: 0

Group type: COMPARATOR
Intervention: HIV-negative individuals
Number of subjects: 0
Study: 16871763

Group type: COMPARATOR
Intervention: Superficial vein reflux detected by ultrasonography
Number of subjects: 100

Group type: COMPARATOR
Intervention: Primary venous insufficiency
Number of subjects: 100

Group type: COMPARATOR
Intervention: Overweight and obesity
Number of subjects: 100

Group type: COMPARATOR
Intervention: Primary valvular insufficiency
Number of subjects: 100

Group type: COMPARATOR
Intervention: Secondary valvular insufficiency (post-thrombotic, post-traumatic)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Gender comparison
Number of subjects: 100
Study: 12888870

Group type: EXPERIMENTAL
Intervention: Antithrombin infusions
Number of subjects: 0

Group type: COMPARATOR
Intervention: No antithrombin treatment (control)
Number of subjects: 0
Study: 10877248

Group type: EXPERIMENTAL
Intervention: UVB treatment with optimized doses based on skin pigmentation measurements
Number of subjects: 20

Group type: COMPARATOR
Intervention: Conventional UVB treatment regimen with fixed dose increments
Number of subjects: 20
Study: 1563884

Group type: EXPERIMENTAL
Intervention: Fish oil supplementation (10 capsules, 3 g per day, containing 1.8 g eicosapentaenoic acid and 1.2 g docosahexaenoic acid)
Number of subjects: 107

Group type: COMPARATOR
Intervention: Conventional medical treatment (aspirin and calcium blockers)
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Fish oil supplementation
Number of subjects: 107

Group type: COMPARATOR
Intervention: Conventional medical treatment
Number of subjects: 107
Study: 3528402

Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 122

Group type: COMPARATOR
Intervention: Surgical oophorectomy
Number of subjects: 122
Study: 30068323

Group type: EXPERIMENTAL
Intervention: 3D heart model
Number of subjects: 63

Group type: COMPARATOR
Intervention: Control group (no 3D heart model)
Number of subjects: 63
Study: 27741340

Group type: EXPERIMENTAL
Intervention: Secukinumab 300 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Secukinumab 150 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 24934214

Group type: EXPERIMENTAL
Intervention: Context A1B1 during acquisition training with cue Z
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Context A2B2 during extinction trials with cue Z
Number of subjects: 0
Study: 22612765

Group type: EXPERIMENTAL
Intervention: Individually tailored oral health educational programme (ITOHEP) based on cognitive behavioural strategies
Number of subjects: 113

Group type: COMPARATOR
Intervention: Standard treatment programme (ST)
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Individually tailored oral health educational programme (ITOHEP)
Number of subjects: 113
Study: 20167644

Group type: EXPERIMENTAL
Intervention: Perturbation-based balance training program
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control program (flexibility and relaxation training)
Number of subjects: 30
Study: 18242145

Group type: EXPERIMENTAL
Intervention: lumiracoxib 100 mg once daily
Number of subjects: 152

Group type: COMPARATOR
Intervention: naproxen 500 mg twice daily plus omeprazole 20 mg once daily
Number of subjects: 152

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 152
Study: 20026883

Group type: EXPERIMENTAL
Intervention: Element ankle brace with subtalar locking system
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Functional ankle brace
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: ASO ankle brace
Number of subjects: 19

Group type: COMPARATOR
Intervention: No brace condition
Number of subjects: 19
Study: 15207981

Group type: EXPERIMENTAL
Intervention: Clinical skin check
Number of subjects: 3110

Group type: EXPERIMENTAL
Intervention: Skin self-examination
Number of subjects: 3110

Group type: EXPERIMENTAL
Intervention: History of clinical skin examination
Number of subjects: 3110

Group type: EXPERIMENTAL
Intervention: Concern about skin cancer
Number of subjects: 3110

Group type: EXPERIMENTAL
Intervention: Personal history of skin cancer
Number of subjects: 3110

Group type: EXPERIMENTAL
Intervention: High susceptibility towards skin cancer
Number of subjects: 3110

Group type: EXPERIMENTAL
Intervention: Gender (Men vs Women)
Number of subjects: 3110
Study: 11688250

Group type: EXPERIMENTAL
Intervention: Erythropoietin administration
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no erythropoietin)
Number of subjects: 0
Study: 9393422

Group type: EXPERIMENTAL
Intervention: Preoperative antibiotics
Number of subjects: 2641

Group type: COMPARATOR
Intervention: Postoperative antibiotics
Number of subjects: 2641
Study: 7895463

Group type: EXPERIMENTAL
Intervention: Glibenclamide
Number of subjects: 22

Group type: COMPARATOR
Intervention: Gliclazide
Number of subjects: 22
Study: 3555571

Group type: EXPERIMENTAL
Intervention: Salbutamol 0.1 mg kg‐1
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31558416

Group type: EXPERIMENTAL
Intervention: DASH diet intervention
Number of subjects: 81

Group type: COMPARATOR
Intervention: Control group (no dietary intervention)
Number of subjects: 81
Study: 31517821

Group type: EXPERIMENTAL
Intervention: ECOG‐PS 0/1 and mGPS0
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: ECOG‐PS 0/1 and NPS0
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Increasing ECOG‐PS
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Increasing mGPS
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Increasing NPS
Number of subjects: 40
Study: 27391041

Group type: EXPERIMENTAL
Intervention: Heart rate variability-based assessment of anaerobic threshold (HRVT2)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Spiro-ergometry testing for second ventilatory threshold (VT2)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Comparison of HRVT2 and VT2
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Assessment under normoxic conditions
Number of subjects: 11
Study: 26883609

Group type: EXPERIMENTAL
Intervention: Articaine
Number of subjects: 102

Group type: COMPARATOR
Intervention: Lidocaine
Number of subjects: 102
Study: 23807984

Group type: EXPERIMENTAL
Intervention: Gynofit (vaginal and perineal dose)
Number of subjects: 120
Study: 21144773

Group type: EXPERIMENTAL
Intervention: Pentoxifylline (PTF) 1200 mg/day for 24 months
Number of subjects: 169

Group type: COMPARATOR
Intervention: Control group (RAS blockade only)
Number of subjects: 169
Study: 19238310

Group type: EXPERIMENTAL
Intervention: Lunch with capsaicin (CAPS)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Lunch without capsaicin (Control)
Number of subjects: 30
Study: 16723781

Group type: EXPERIMENTAL
Intervention: G643S carriers (n=88)
Number of subjects: 992

Group type: COMPARATOR
Intervention: Control group (G643G, n=243)
Number of subjects: 992
Study: 16089261

Group type: EXPERIMENTAL
Intervention: Whiteness Perfect‐‐10% carbamide peroxide (10% CP)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Colgate Platinum‐‐10% carbamide peroxide (10% CP)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Day White 2Z‐‐7.5% hydrogen peroxide (7.5% HP)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Whiteness Super‐‐3% CP
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Opalescence Quick‐‐35% CP
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Whiteness HP‐‐35% HP
Number of subjects: 77

Group type: COMPARATOR
Intervention: Control (not treated, stored in artificial saliva)
Number of subjects: 77
Study: 11305263

Group type: EXPERIMENTAL
Intervention: High-phosphorus diet (3008 mg P and 1995 mg Ca/day for 6 weeks)
Number of subjects: 10
Study: 9053501

Group type: EXPERIMENTAL
Intervention: Docetaxel 75 mg/m2 followed by cisplatin 100 mg/m2
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Docetaxel 100 mg/m2 followed by cisplatin 75 mg/m2
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Docetaxel 75 mg/m2 and cisplatin 75 mg/m2
Number of subjects: 24
Study: 7952551

Group type: EXPERIMENTAL
Intervention: Budesonide 800 micrograms twice daily
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Terbutaline 1,000 micrograms three times daily
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Budesonide plus Terbutaline
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study: 3311769

Group type: EXPERIMENTAL
Intervention: Screening-detected cancers
Number of subjects: 964

Group type: COMPARATOR
Intervention: Clinically detected cancers
Number of subjects: 964

Group type: EXPERIMENTAL
Intervention: Smaller tumours detected by screening
Number of subjects: 964

Group type: COMPARATOR
Intervention: Larger tumours
Number of subjects: 964
Study: 29533368

Group type: EXPERIMENTAL
Intervention: YYSG (Chinese herbal medicine capsules)
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: YYSG
Number of subjects: 146

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 146
Study: 27871564

Group type: EXPERIMENTAL
Intervention: Remifentanil
Number of subjects: 622

Group type: COMPARATOR
Intervention: Fentanyl
Number of subjects: 622
Study: 24314839

Group type: EXPERIMENTAL
Intervention: Ranibizumab or bevacizumab treatment (specific drug not detailed)
Number of subjects: 1059

Group type: EXPERIMENTAL
Intervention: Classic choroidal neovascularization (CNV)
Number of subjects: 1059

Group type: EXPERIMENTAL
Intervention: Foveal retinal thickness >212 μm
Number of subjects: 1059

Group type: EXPERIMENTAL
Intervention: Foveal subretinal tissue complex thickness >275 μm
Number of subjects: 1059

Group type: EXPERIMENTAL
Intervention: Foveal subretinal fluid
Number of subjects: 1059

Group type: EXPERIMENTAL
Intervention: Subretinal hyperreflective material (SHRM)
Number of subjects: 1059

Group type: EXPERIMENTAL
Intervention: Elevation of the retinal pigment epithelium
Number of subjects: 1059

Group type: EXPERIMENTAL
Intervention: Fibrotic scars
Number of subjects: 1059

Group type: EXPERIMENTAL
Intervention: Nonfibrotic scars
Number of subjects: 1059
Study: 22771050

Group type: EXPERIMENTAL
Intervention: AXOS 4.8 g/d
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: AXOS 2.2 g/d
Number of subjects: 55

Group type: COMPARATOR
Intervention: Control (0 g/d AXOS)
Number of subjects: 55
Study: 19027970

Group type: EXPERIMENTAL
Intervention: Irbesartan 300 mg/day
Number of subjects: 89

Group type: COMPARATOR
Intervention: Increased dose of ACE inhibitor
Number of subjects: 89
Study: 17655810

Group type: EXPERIMENTAL
Intervention: Conventional polypropylene membrane oxygenator
Number of subjects: 20

Group type: COMPARATOR
Intervention: Plasma-tight poly-(4-methyl-1-pentene) membrane oxygenator
Number of subjects: 20
Study: 16243127

Group type: EXPERIMENTAL
Intervention: Doxycycline hyclate 20 mg plus metronidazole 0.75% topical lotion
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo plus metronidazole 0.75% topical lotion
Number of subjects: 40
Study: 12149101

Group type: EXPERIMENTAL
Intervention: Smoking cessation for 1 week
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Alcohol restriction for 3 weeks
Number of subjects: 68
Study: 9800666

Group type: EXPERIMENTAL
Intervention: Esterified estrogens + androgen
Number of subjects: 20

Group type: COMPARATOR
Intervention: Esterified estrogens
Number of subjects: 20
Study: 8119599

Group type: EXPERIMENTAL
Intervention: Hemorheological manipulation including plasma expansion with hydroxyethyl-starch, withdrawal of whole blood if hematocrit was above 42%, and parenteral pentoxifylline.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified in detail).
Number of subjects: 0
Study: 2605993

Group type: EXPERIMENTAL
Intervention: Active marijuana (0-2.7% delta 9 THC), 4 cigarettes smoked daily, 2 prior to and 2 during social access period.
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Active marijuana (0-2.7% delta 9 THC)
Number of subjects: 12
Study: 786676

Group type: EXPERIMENTAL
Intervention: 1 mg of AN 448 t.i.d.
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 30518495

Group type: EXPERIMENTAL
Intervention: 4-week exercise programme based on aerobic interval and resistance training
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (CG) did not participate in any physical activity
Number of subjects: 20
Study: 27160187

Group type: EXPERIMENTAL
Intervention: Hospital Value-Based Purchasing (HVBP) program
Number of subjects: 2430618

Group type: COMPARATOR
Intervention: Non-HVBP hospitals (control)
Number of subjects: 2430618

Group type: COMPARATOR
Intervention: Comparison of HVBP vs Non-HVBP hospitals
Number of subjects: 2430618

Group type: EXPERIMENTAL
Intervention: Subgroup of poor performers at baseline
Number of subjects: 2430618
Study: 24884731

Group type: EXPERIMENTAL
Intervention: 20% mannitol at 0.7 g/kg
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: 20% mannitol at 1.0 g/kg
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: 20% mannitol at 1.4 g/kg
Number of subjects: 220

Group type: COMPARATOR
Intervention: Control group (no mannitol)
Number of subjects: 220
Study: 22293541

Group type: EXPERIMENTAL
Intervention: 37.5 mg or 75 mg roxatidine capsules given orally to pediatric patients
Number of subjects: 0

Group type: COMPARATOR
Intervention: 37.5 mg, 75 mg or 150 mg roxatidine capsules given to healthy adult volunteers
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Multiple-dose study of roxatidine in pediatric patients
Number of subjects: 0
Study: 20386783

Group type: EXPERIMENTAL
Intervention: Grafted sockets
Number of subjects: 16

Group type: COMPARATOR
Intervention: Untreated sockets (Control)
Number of subjects: 16
Study: 17198763

Group type: EXPERIMENTAL
Intervention: Rehabilitative ultrasound imaging (RUSI) during hypertonic saline condition
Number of subjects: 6

Group type: COMPARATOR
Intervention: Rehabilitative ultrasound imaging (RUSI) during control condition
Number of subjects: 6
Study: 15974219

Group type: EXPERIMENTAL
Intervention: KNO3 plus fluoride dentifrice (Sensodyne Fresh Mint)
Number of subjects: 202

Group type: COMPARATOR
Intervention: Standard fluoride dentifrice (Crest Regular)
Number of subjects: 202
Study: 12839657

Group type: EXPERIMENTAL
Intervention: Potassium and calcium supplementation in table salt (10 mmol each daily for 24 months)
Number of subjects: 220

Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 220
Study: 11089594

Group type: EXPERIMENTAL
Intervention: Oral sodium phosphate solution
Number of subjects: 323

Group type: COMPARATOR
Intervention: Polyethylene glycol with bisacodyl
Number of subjects: 323
Study: 9369819

Group type: EXPERIMENTAL
Intervention: Induction with intravenous oxytocin
Number of subjects: 5041

Group type: EXPERIMENTAL
Intervention: Induction with vaginal prostaglandin E2 gel
Number of subjects: 5041

Group type: EXPERIMENTAL
Intervention: Expectant management with induction if needed
Number of subjects: 5041
Study: 1555145

Group type: EXPERIMENTAL
Intervention: Indwelling catheter (removed 48 hours post-surgery)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Intermittent catheterization (every 6 to 8 hours)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Indwelling catheter
Number of subjects: 67

Group type: COMPARATOR
Intervention: Intermittent catheterization
Number of subjects: 67
Study: 3925430

Group type: EXPERIMENTAL
Intervention: Nonacetylated group C polysaccharide C(OAc‐)
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Acetylated group C polysaccharide C(OAc+)
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Both vaccines (C(OAc‐) and C(OAc+))
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Both vaccines
Number of subjects: 118
Study: 30727931

Group type: EXPERIMENTAL
Intervention: Direct Antiviral Agents (DAAs), sofosbuvir-based therapies for 12 weeks
Number of subjects: 1716
Study: 28930864

Group type: EXPERIMENTAL
Intervention: Dexamethasone (8 mg·d)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 26704571

Group type: EXPERIMENTAL
Intervention: PASS (parent-mediated intervention)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 65
Study: 24112634

Group type: EXPERIMENTAL
Intervention: Femtosecond lenticule extraction (FLEx)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Small-incision lenticule extraction (SMILE)
Number of subjects: 26
Study: 22041022

Group type: EXPERIMENTAL
Intervention: 225 ppm F
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: 225 ppm F plus fTCP
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: 450 ppm F
Number of subjects: 80

Group type: COMPARATOR
Intervention: Fluoride-free (0 ppm F)
Number of subjects: 80
Study: 21804894

Group type: EXPERIMENTAL
Intervention: Tubigrip
Number of subjects: 79

Group type: COMPARATOR
Intervention: Plaster cast
Number of subjects: 79

Group type: COMPARATOR
Intervention: Futuro splints
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Ultrasound
Number of subjects: 79

Group type: COMPARATOR
Intervention: X‐rays
Number of subjects: 79
Study: 17652295

Group type: EXPERIMENTAL
Intervention: 1-sided hip protector on the left or right hip
Number of subjects: 1042

Group type: COMPARATOR
Intervention: Unprotected hips
Number of subjects: 1042

Group type: EXPERIMENTAL
Intervention: 1-sided hip protector on the left or right hip (for residents with >80% adherence)
Number of subjects: 1042

Group type: COMPARATOR
Intervention: Unprotected hips (for residents with >80% adherence)
Number of subjects: 1042
Study: 16247129

Group type: EXPERIMENTAL
Intervention: Left posterior oblique (LPO) position during CT gastrography
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard supine position during CT gastrography
Number of subjects: 0
Study: 11159230

Group type: EXPERIMENTAL
Intervention: Tramadol 100 mg every 6 h
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Metamizol 1 g every 6 h
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Paracetamol 1 g every 6 h
Number of subjects: 120